为解决肾癌预后评估和治疗难题，首都医科大学研究人员开展 MAGI3 相关研究。发现 MAGI3 可影响肾癌对舒尼替尼敏感性且是预后标志物。该研究为肾癌精准治疗提供新思路，强烈推荐科研读者阅读。

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.